| Line Item | 2026-03-31 | Y/Y |
|---|---|---|
| Revenue | $1.3M | +161.1% |
| R&D Expense | $55.0M | +39.6% |
| SG&A Expense | $18.4M | +7.8% |
| Operating Income | -$72.1M | -28.9% |
| Pre-tax Income | -$69.7M | -35.5% |
| Income Tax | $7K | +0.0% |
| Net Income | -$69.7M | -35.5% |
| EPS (Basic) | -$1.83 | -9.6% |
| EPS (Diluted) | -$1.83 |
| Line Item | 2026-03-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $30.8M | -54.1% |
| Current Assets | $46.9M | -42.8% |
| Total Assets | $48.6M | -42.4% |
| Current Liabilities | $12.8M | +1.5% |
| Total Liabilities | $13.0M | -6.5% |
| Stockholders' Equity | $35.5M | -49.5% |
| Line Item | 2026-03-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$66.4M | -57.8% |
| Investing Cash Flow | -$877K | +93.3% |
| Financing Cash Flow | $31.0M | +864.8% |
Business Overview
Pherin Pharmaceuticals is a late clinical-stage biopharmaceutical company developing intranasal pherine product candidates targeting neurological and psychiatric indications through nose-to-brain neurocircuitry mechanisms. The company's lead candidate, fasedienol, is in Phase 3 registration-directed trials (PALISADE Program) for acute social anxiety disorder treatment, with PALISADE-2 achieving its primary efficacy endpoint in August 2023, while PALISADE-1 and PALISADE-3 did not meet primary endpoints. In March 2026, the company implemented a 20% workforce reduction to prioritize cash management while advancing ongoing clinical studies, particularly the PALISADE-4 trial expected to report results in Q2 2026.
Segment Performance
The company does not report traditional business segments. R&D expenses increased 39.6% from $39.4 million (fiscal 2025) to $55.0 million (fiscal 2026), driven primarily by higher fasedienol PALISADE Program activity ($38.5 million vs. $21.9 million), including concurrent Phase 3 trials and repeat dose studies. Other clinical candidate spending decreased from $3.1 million to $1.2 million as resources prioritized the PALISADE Program. G&A expenses increased 7.8% from $17.1 million to $18.4 million, primarily due to legal expenses and shareholder litigation defense. Sublicense and other revenue increased from $0.5 million to $1.3 million.
Forward Guidance
"We expect to announce topline results from the randomized portion of PALISADE-4 in the second quarter of calendar 2026." The company stated expectations that "our general and administrative expenses may increase substantially over the next fiscal year in the event of positive results from PALISADE-4" for NDA preparation and commercialization, but "in the event of negative results from PALISADE-4, we expect to further cash conservation efforts, resulting in an anticipated decrease to general and administrative expense." The company noted it "cannot accurately estimate or know the nature, timing and costs" of future R&D efforts and plans to "seek substantial additional financing" though "no assurance can be provided that any such sales of securities, awards, agreements or collaborations will occur."
| -9.6% |
Key Risk Factors
The company faces substantial risks including dependency on obtaining additional financing to continue operations; uncertainty in successfully completing clinical trials and obtaining regulatory approval for product candidates; reliance on third-party collaborators for development, manufacturing, and commercialization outside management's control; FDA and other regulatory agency oversight and changing healthcare regulations; patent protection challenges; competition from other product developments; and potential inability to raise capital without significant dilution, with substantial doubt about going concern status as of June 15, 2026.